StockIQpro
NASDAQ:AQST

Aquestive Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Aquestive Therapeutics, Inc.'s revenue fell 22.6% in fiscal 2025 to $44.5M while operating margin fell to −159.5%, its lowest in 9 years. Free cash flow was −$53.0M, −119.0% of revenue, and the diluted share count rose 23.3%.Summary generated from Aquestive Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 4, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$44.5M
Revenue growth−22.6%
Revenue, 5-yr CAGR−0.6%
Gross margin58.3%
Operating margin−159.5%
Net margin−188.1%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$53.0M
FCF margin−119.0%
Share count change+23.3%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue5148515845
Operating income−35−42−15−31−71
Net income−71−54−8−44−84
Free cash flow−34−11−7−36−53

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations